← Back to research
Research ArticlePubMed

Icotrokinra Achieves 50% PASI 90 in Phase 3 ICONIC-LEAD Trial for Plaque Psoriasis

Summary

The first oral peptide targeting the IL-23 receptor delivered 65% IGA 0/1 and 50% PASI 90 responses at week 16 in adults and adolescents with moderate-to-severe plaque psoriasis, significantly outperforming placebo in this NEJM-published Phase 3 RCT.

Bottom line: Icotrokinra is the first oral peptide to achieve biologic-level skin clearance in plaque psoriasis, offering prescribers a once-daily pill alternative to injectable IL-23 inhibitors.

Icotrokinra (ICOTYDE, Johnson & Johnson / Protagonist Therapeutics) is a constrained cyclic peptide engineered to survive gastrointestinal transit and selectively block the IL-23 receptor — a cytokine pathway central to the pathogenesis of psoriasis and other inflammatory conditions.

ICONIC-LEAD Trial Design

The Phase 3 ICONIC-LEAD trial, published in the New England Journal of Medicine, was a double-blind, randomized, placebo-controlled study enrolling 684 adults and adolescents with moderate-to-severe plaque psoriasis.1 Participants were randomized 2:1 to receive oral icotrokinra or placebo, with co-primary endpoints of IGA 0/1 response and PASI 90 response at week 16.

Key Findings

At week 16:1

  • IGA 0/1 response: 65% icotrokinra vs. 8% placebo (p < 0.001)
  • PASI 90 response: 50% icotrokinra vs. 4% placebo (p < 0.001)
  • The treatment effect was consistent across adults and adolescents
  • No new safety signals were identified through 16 weeks

Longer-term 52-week data from the ICONIC-ADVANCE 1 and 2 companion studies, presented at AAD 2026, confirmed durable clearance with a favorable safety profile through one year of treatment.2

Why This Matters

Plaque psoriasis affects approximately 7.5 million adults in the United States alone. While injectable biologics targeting IL-23 (such as guselkumab, risankizumab, and tildrakizumab) have transformed outcomes, many patients prefer oral therapy. The only prior oral option — deucravacitinib (Sotyktu), a TYK2 inhibitor — was outperformed by icotrokinra in the Phase 3 ICONIC-ADVANCE head-to-head studies.2

The ability to deliver selective IL-23 receptor blockade via a once-daily pill represents a pharmacological milestone for peptide drug design. Icotrokinra's constrained cyclic structure protects it from proteolytic degradation, enabling oral bioavailability — a longstanding challenge for peptide therapeutics.

Clinical implication: Icotrokinra gives dermatologists a potent oral alternative for patients who refuse or cannot tolerate injectable biologics, with efficacy rivaling subcutaneous IL-23 inhibitors.

For more on peptide therapies in dermatology, see our guides on IL-23 pathway biology and oral peptide drug design.


References

  1. Bissonnette R, Soung J, et al. Oral icotrokinra for plaque psoriasis in adults and adolescents. N Engl J Med. 2026. DOI: 10.1056/NEJMoa2504187. PMID: 41191940.
  2. Johnson & Johnson. ICOTYDE (icotrokinra) one-year results confirm lasting skin clearance. Press release, March 30, 2026.

Investigación Relacionada